Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2005

View Archived Issues

Merck describes novel compounds for obesity and related eating disorders

NP-0361 shows promise in the treatment of Alzheimer's

In vivo evidence that a 5-HT2A/2C receptor agonist elevates sexual activity

Methylene blue in the treatment of prolonged pharmaco-induced erection

Selective 5-HT6 receptor antagonist improves memory acquisition in rats / News in Context

OncoGenex Technologies and Isis broaden antisense partnership

Cetrorelix enters development for endometriosis and BPH

FDA Advisory Committee recommends approval of Boostrix

Sonus reviews Tocosol Paclitaxel progress, terminates Synt:em acquisition

Arpida set to advance injectable iclaprim into global phase III program

PEP-005 Topical enters phase II

Phase I study of XL-880 in solid tumor patients

Neurogenetics changes name to TorreyPines Therapeutics

Positive results from pilot PK study of ondansetron lingual spray

Two CS-917 studies terminated after serious adverse events

TAP compound huMy9-6-DM4 enters clinical testing

GTC Biotherapeutics awaits EMEA comments regarding ATryn MAA

Galangin shows promise as a treatment for bladder dysfunction / News in Context

Serono identifies 80 genes involved in MS

First clinical evidence for the benefits of R-pramipexole in ALS

New data presented on the PK profile of alvimopan and DA-6034 at the ASCPT

The STAR study confirms the greater efficacy of solifenacin in OAB

BXL-628 reduces prostate volume in patients with BPH

Phase II trial on the efficacy of tgAAVCF in cystic fibrosis fails to meet primary endpoint

New treatments for bone disorders reported in patent literature

Recent patents describe treatments for cancer

New mechanism described for angiogenesis inhibitors TNP-470 and caplostatin

Antitumor activity of the Plk-1 inhibitor ON-01910 / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...